-
Frontiers in Immunology: Validation of GWAS-identified variants in response to anti-TNF drugs in rheumatoid arthritis: a meta-analysis of two large cohorts
Time of Update: 2021-12-02
Results: including 2067 Ming RA discovery cohort including patients and DREAM analysis showed that meta-registry, LINC02549 rs7767069 SNP and DAS28 between a lower overall improvement in the presence of association remained significant after multiple testing correction difference (each Allele OR Meta =0.
-
Frontiers in Immunology: Galectin-9 regulates the gouty inflammation induced by sodium urate crystals by adjusting the ratio of Treg/Th17
Time of Update: 2021-12-02
In this study, the investigators comprehensively characterized the induction of exogenous Gal-9 in MSU crystals by monitoring the phenotype of in situ neutrophils, monocytes and Th17/Treg recruitment and related chemokine profiles.
-
ARD: Severe delayed hypersensitivity to IL-1 and IL-6 inhibitors is related to the common HLA-DRB1*15 allele
Time of Update: 2021-12-02
Methods : In a case / control study, the investigator collected a multicenter series of Still disease patients with inhibitor-related DRESS (n=66) and drug-resistant Still controls (n=65) .
Summary : DRESS -type reactions occur in patients treated with IL-1/IL-6 inhibitors and are closely related to the common HLA-DRB1*15 haplotype .
-
Frontiers in Immunology: CRAC channel controls the differentiation of pathogenic B cells in lupus nephritis
Time of Update: 2021-12-02
In in vitro studies, YM-58483 's inhibition of CRAC channels or the down-regulation of ORAI1- specific small interfering RNA (siRNA) reduced Ca2+/ calmodulin-dependent protein kinase 2 (CaMK2) phosphorylation and inhibited human B cells Expression of Blimp-1 , leading to B cell differentiation and immunoglobulin G (IgG) Produce reduction .
-
J INTERN MED: The risk of recurrence of ANCA-related vasculitis in patients 75 years and older is lower than that in younger patients
Time of Update: 2021-12-02
Although the possibility of receiving a combination of glucocorticoid and immunosuppressant maintenance therapy is low, the risk of recurrence of AAV patients over 75 years is lower than that of patients 65-75 years old, but they still benefit from this treatment .
-
New long-term positive data for JAK inhibitor Olumiant in RA
Time of Update: 2021-12-02
as one of the safety test JAK inhibitors in this disease the longest, these data can help health care providers and patients with rheumatoid arthritis when considering treatment options can be used to better understand the long-term Olumiant" .
-
2021 American Academy of Rheumatology Annual Meeting｜Research progress on gout medication
Time of Update: 2021-12-02
November 9th, 10:30-10:45, Beijing time, Nicola Dalbeth and other scholars shared the topic of "A Randomized Double-Blind Controlled Trial of Intensive Serum Urate Lowering with Oral Urate-Lowering Therapy for Erosive Gout" Research progress .
org/abstract/a-randomized-double-blind-controlled-trial-of-intensive-serum-urate-lowering-with-oral-urate-lowering-therapy-for-erosive-gout/#cancelhttps://acrabstracts.
-
From the 4 major categories of indicators, teach you to develop a wind-like review plan!
Time of Update: 2021-12-02
Then, in the course of treatment, it is necessary to combine the changes of the disease at any time, review the relevant indicators regularly, and adjust to the best treatment effect and drug dosage by judging whether the disease is in the active phase, the degree of activity, and whether the joint damage is progressing .
-
ARD: Single-cell transcriptome analysis can identify skin-specific T cell responses in systemic sclerosis
Time of Update: 2021-12-02
The droplet-based single-cell transcriptome analysis of immune SSc skin biopsy opens up a way to analyze patient-specific T cell heterogeneity and provides a basis for identifying new gene expression related to functional pathways related to the severity of SSc skin diseases .
-
Frontiers in Immunology: IL-40: A new B-cell-related cytokine is up-regulated and decreased after rituximab treatment of rheumatoid arthritis, and is associated with disease activity, autoantibodies and NETosis
Time of Update: 2021-12-02
Compared with the overexpression in synovial tissues, especially the synovial lining and infiltrating immune cells in OA patients, the level of IL-40 in the synovial fluid of RA patients was up-regulated ( p<0.
-
The rare first manifestation of SLE-mesenteric vasculitis
Time of Update: 2021-12-02
GIT-related symptoms are very common in SLE patients, with an incidence of as high as 40%-50%, and almost any organ related to GIT is involved .
Mesenteric vasculitis as a rare initial presentation of systemic lupus erythematosus: A case report.
-
2021ACR: Allopurinol and benzbromarone in the treatment of cardiovascular risk in patients with gout
Time of Update: 2021-12-02
Although many studies have explored the treatment of gout patients with uric acid lowering heart vascular risk impact, but few studies have focused on the "Compare allopurinol and benzbromarone impact on cardiovascular risk in patients with gout difference" .
-
Nat Med: Febutinib in the treatment of chronic spontaneous urticaria refractory to H1 antihistamines
Time of Update: 2021-12-02
This double-blind, placebo-controlled phase 2 trial (EudraCTID2016-004624-35) randomized 93 adults with antihistamine-refractory CSU They were assigned to the febutinib treatment group or placebo group at 50 mg per day, 150 mg per day, and 200 mg twice a day, and continued treatment for 8 weeks .
-
Arthritis Rheumatol: Differences in oral microbes between patients with rheumatoid arthritis and healthy people
Time of Update: 2021-12-02
This study evaluated the differences in oral microbiome and periodontal status between early RA patients and individuals at risk of RA compared with healthy controls .
There were no significant differences in the three periodontal indicators of early RA patients, high-risk individuals, and healthy controls (BOP P = 0.
-
Chest: Analysis of the effect of rituximab treatment on primary prevention of Pneumocystis jiroveci pneumonia
Time of Update: 2021-12-02
InfectIt can be seen that in patients receiving rituximab treatment, TMP-SMX prevention significantly reduces the incidence of PJP, and the safety is acceptable .
In patients receiving rituximab treatment, TMP-SMX prevention significantly reduced the incidence of PJP, and the safety was fair .
-
Eating Tripterygium wilfordii at night is better for rheumatoid arthritis
Time of Update: 2021-12-02
Tripterygium wilfordii polyglycoside tablets are clinically one of the most commonly used botanical preparations for the treatment of rheumatoid arthritis (RA). They are often used in combinat
-
ACR 2021: A meta-analysis of pregnancy outcomes in Behcet's disease
Time of Update: 2021-12-02
The purpose of our work is to assess the prevalence of fetal and maternal complications through systematic reviews and meta-analysis to determine the impact of Behcet's disease on pregnancy .
Behcet's Disease: A Meta-analysis of Pregnancy Outcomes [ abstract].
org/abstract/behcets-disease-a-meta-analysis-of-pregnancy-outcomes/.
-
Lancet Rheumatology: The efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomized, placebo-controlled, proof-of-concept trial
Time of Update: 2021-12-02
Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial.
Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial.
-
1 case of extremely rare autoimmune disease
Time of Update: 2021-12-02
The second episode of epilepsy was treated in the hospital, and hypoglycemia, various bacterial encephalitis, viral encephalitis, toxic encephalitis, Hashimoto's encephalopathy, central system demyelinating disease were ruled out, and the final diagnosis: autoimmune polyendocrine Adenopathic syndrome type III, Graves disease, autoimmune limbic encephalitis (GAD-mediated), thymoma .
-
Arsenic may be used in the treatment of systemic lupus erythematosus
Time of Update: 2021-12-02
Recently, a research team from the University of Nantes in France published a study in Arthritis Research & Therapy, showing that low-dose intravenous ATO has better efficacy and safety in the treatment of systemic lupus erythematosus (SLE) .
